Liverpool Uni researchers given £1.5m for pancreatic cancer study
Scientists at the University of Liverpool have been awarded £1.5 million by Cancer Research UK for work that aims to boost understanding about pancreatic cancer.
12th February 2018
Latest news
Boehringer ends development of Alzheimer’s candidate
Boehringer Ingelheim is ending development of BI 409306 in Alzheimer's disease on disappointing mid-stage trial data.
12th February 2018
Roche’s Gazyvaro gets NICE nod for high-risk lymphoma patients
Cost regulators for NHS treatments in England and Wales have now recommended funding for Roche’s Gazyvaro for some patients with untreated follicular lymphoma, after the submission of new data by the company.
12th February 2018
NICE asks Tesaro to submit CDF application for Zejula
Tesaro has been asked by NICE to submit a proposal for Zejula use on the National Health Service via the Cancer Drugs Fund for maintenance treatment of patients with relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer.
9th February 2018
Liver cancer patients barred from NHS access to Bayer’s Stivarga
It is now looking very unlikely that patients with liver cancer will get access to Bayer’s Stivarga on the NHS, after cost regulators issued final draft guidelines rejecting funding for the drug in this setting.
9th February 2018
UK launch for Bayer’s five-year contraceptive Kyleena
A new long-acting reversible contraception method offering protection from unplanned pregnancy for up to five years has been launched in the UK.
9th February 2018
ViiV kicks off PhIII trial of two-drug HIV regimen
ViiV Healthcare, an HIV specialist firm majority owned by GlaxoSmithKline, has announced the launch of a late-stage study investigating the effectiveness of a two-drug regimen programme in patients with HIV.
9th February 2018
Biogen reveals Tysabri failure in stroke trial
Biogen has confirmed that it will not pursue further development of Tysabri in acute ischemic stroke (AIS) after a mid-stage study missed primary and secondary efficacy goals.
9th February 2018
GSK happy with 3 percent rise in 2017 sales
GlaxoSmithKline has reported a sales hike of 3 percent at constant exchange rates (CER*) for 2017, after growth was recorded across all of its three global businesses.
8th February 2018
Scientists discover way to halt breast cancer spread
Scientists have uncovered a key mechanism that facilitates the spread of breast cancer cells, and thus a potential target for new therapeutic approaches in the fight against the disease.
8th February 2018
Theravance Ireland signs deal with Janssen Biotech
Theravance Biopharma Ireland has signed a global co-development and commercialisation deal with Janssen Biotech focusing on new treatments for inflammatory intestinal conditions, including ulcerative colitis and Crohn’s disease.
8th February 2018
US green light for Gilead’s HIV combo
Gilead’s new combination therapy Biktarvy has been approved by the US Food and Drug Administration for the treatment of HIV.
8th February 2018
Trial success for Allergan’s anti-CGRP migraine drug
The first of two pivotal Phase III clinical trials evaluating Allergan’s experimental anti-CGRP migraine drug ubrogepant has met its key goal.
7th February 2018
Catapult brokers ‘double-blind’ research alliance with Dundee Uni, ADS
The Medicines Discovery Catapult has brokered a deal between Antimicrobial Discovery Solutions and the University of Dundee to create a neutral space for research into new antimicrobial drugs.
7th February 2018
Scotland’s TCB inks CAR-T deal with Japan’s NIPRO
Scotland’s TC Biopharm (TCB) has secured a major investment from Japan with a deal centered on developing a novel gamma-delta CAR-T therapy to treat cancer, as well as a grant from Scottish Enterprise worth £2.7 million to fund preclinical activities.
7th February 2018
